<DOC>
	<DOCNO>NCT00640250</DOCNO>
	<brief_summary>We propose prospective , multi-center , double-blind , randomize study compare diagnostic performance ( primary ) safety ( secondary ) 3 concentration Disperse blue 106 4 concentration Bronopol 40 adult subject ( 20 subject per allergen ) clinical history contact dermatitis positive patch test ( current previous ) correspond reference petrolatum allergen ( `` sensitive '' ) .</brief_summary>
	<brief_title>Clinical Evaluation T.R.U.E . TESTÂ® Panel 3.2 Allergens : Dose Response</brief_title>
	<detailed_description>Primary endpoint : To evaluate diagnostic performance Disperse blue 106 Bronopol T.R.U.E . Test allergens 20 adult subject per allergen clinical history contact dermatitis positive patch test respective reference allergen . Evaluations include : - Determination low concentration elicit positive skin reaction ( +1 +2 ) 70-90 % sensitive subject . - Frequency positive , negative , doubtful irritant reaction allergen test concentration . - Concordance/discordance compare corresponding reference petrolatum allergen . Secondary endpoint : To evaluate safety Disperse blue 106 Bronopol T.R.U.E . Test allergens 20 adult subject per allergen clinical history contact dermatitis positive patch test respective reference allergen . Evaluations include : - The frequency tape-induced irritation test site , incomplete panel adhesion , subject-reported sensation itch burning . - The frequency characterization adverse event serious adverse event . - The frequency characterization late and/or persistent reaction .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Contact</mesh_term>
	<mesh_term>Bronopol</mesh_term>
	<criteria>Current previous symptom and/or history consistent allergic contact dermatitis , positive patch test ( within past 5 year ) Bronopol OR Current previous symptom and/or history consistent allergic contact dermatitis , positive patch test ( within past 5 year ) Disperse blue 106 Disperse blue 106/124 allergen mix . All subject must adults ( 18 year age old ) otherwise good health . Premenopausal female subject must consent urine pregnancy test ; result must negative study inclusion . Informed consent must sign understood subject , consistent institutional , local national regulation . Subjects unable meet inclusion requirement . Women breastfeed pregnant . Topical treatment last 7 day corticosteroid immunosuppressive agent near test area . Systemic treatment last 7 day corticosteroid ( equivalent &gt; 10 mg prednisone ) immunosuppressive agent . Treatment ultraviolet ( UV ) light ( include tan ) previous 3 week . Acute dermatitis outbreak dermatitis near test area back . Subjects unable comply patch test study requirement include multiple return visit activity restriction ( e.g. , protect test panel excess moisture due shower vigorous activity ) . Subject participation clinical trial investigational drug , treatment device T.R.U.E . Test study 3 week prior inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Dermatitis , Contact , Bronopol , Disperse Blue 106</keyword>
</DOC>